Photo: First Post
Bharat Biotech Gets Emergency Use Authorization For Intranasal Vaccine Against Covid-19
Bharat Biotech International Ltd (BBIL) on Tuesday got emergency use authorisation from the Drugs Controller General of India (DCGI) for its intranasal COVID-19 vaccine, announced Union Health Minister Mansukh Mandaviya. With this, Bharat Biotech's intranasal COVID-19 vaccine will be India's first nasal vaccine for the deadly virus in India. The approval came after the Bharat Biotech completed the third and final trial of the drug, used for… read-more
Tags: Intranasal vaccine, Bharat biotech, Union government, DCGI, EUA
Courtesy: The Free Press Journal
Photo: Bharat Biotech Website
DCGI Approves Bharat Biotech's Intranasal COVID-19 Vaccine For Phase III Trials
The Drugs Controller General of India on January 28, approved clinical trials of Intranasal vaccine against COVID-19. Manufactured by Bharat Biotech, the phase III trials will be conducted on 5,000 subjects, who are vaccinated with Covishield or Covaxin, in nine Indian states. If successful after evaluation, the Intranasal vaccine will also be used as booster dose, especially when the nation is fighting COVID-19's new variant Omicron and the… read-more
Tags: Bharat biotech, Intranasal vaccine, Drugs Controller General of India, Hyderabad, Booster shot
Courtesy: Money Control
Photo: Bharat Biotech Website
DCGI Approves Phase III Trial Of Bharat Biotech's Intranasal COVID-19 Vaccine
The Director Control General of India (DCGI) approved phase III trial of Intranasal COVID-19 vaccine, manufactured by Bharat Biotech. On January 4, the Subject Expert Committee (SEC) of the DCGI, approved the report, following which phase III trail will begin on 5,000 subject, 50% Covishield vaccinated people and 50% COVAXIN vaccinated people. If successful, the Intranasal vaccine will be used as booster shot, especially when nation is facing… read-more
Tags: Bharat biotech, DCGI, Intranasal vaccine, Covid-19, omicron
Courtesy: One India
Photo: The Economic Times
Hyderabad's Bharat Biotech Seeks Phase 3 Trial Of Intranasal Vaccine Booster Shot
Hyderabad based Bharat Biotech, on December 20, sough approval for phase 3 trial of its COVID-19 booster shot. The company urged the DCGI to approve trials for intranasal vaccine against COVID-19, especially amid Omicron scare. "The application has been filed and the company is awaiting approval from the drug regulator," reported PTI. Notably, the company already conducted phase I and phase II trials and submitted a detailed report… read-more
Tags: Intranasal vaccine, Covid-19, Bharat biotech, DCGI, Omicron Strain
Courtesy: The Indian Express
